|
|
|
|
Vol. 62, Issue 3, 698-704, September 2002
The Immunopharmacological Research Group, Medical School,
University of Tampere, Tampere, Finland; and Tampere University
Hospital, Tampere, Finland
Nitric oxide (NO) production through the inducible nitric-oxide
synthase (iNOS) pathway is increased in inflammatory diseases and leads
to cellular injury. Anti-inflammatory steroids inhibit the expression
of various inflammatory genes, including iNOS. In the present study, we
investigated the mechanism how dexamethasone decreased NO production in
murine J774 macrophages. Dexamethasone (0.1-10 µM) inhibited the
production of NO and iNOS protein in a dose-dependent manner in cells
stimulated with lipopolysaccharides (LPS). In contrast, in cells
treated with a combination of LPS and interferon-
(IFN-
),
dexamethasone did not reduce iNOS expression and NO formation.
Dissociated glucocorticoid RU24858 inhibited iNOS expression and
NO production to levels comparable with that of dexamethasone,
suggesting that the reduced iNOS expression by dexamethasone is not a
GRE-mediated event. In further studies, the effect of dexamethasone on
iNOS mRNA levels was tested by actinomycin assay. The half-life of iNOS
mRNA after LPS treatment was 5 h 40 min, and dexamethasone reduced
it to 3 h. The increased degradation of iNOS mRNA was reversed by
a protein synthesis inhibitor cycloheximide. iNOS mRNA was more stabile
in cells treated with a combination of LPS plus IFN-
(half-life = 8 h 20 min), and dexamethasone had a minor effect in these
conditions. In conclusion, dexamethasone decreases iNOS-dependent NO
production by destabilizing iNOS mRNA in LPS-treated cells by a
mechanism that requires de novo protein synthesis. Also, decreased iNOS
mRNA and protein expression and NO formation by dexamethasone was not
found in cells treated with a combination of LPS plus IFN-
,
suggesting that the effect of dexamethasone is stimulus-dependent.
This article has been cited by other articles:
![]() |
O. Sareila, M. Hamalainen, E. Nissinen, H. Kankaanranta, and E. Moilanen Orazipone Inhibits Activation of Inflammatory Transcription Factors Nuclear Factor-{kappa}B and Signal Transducer and Activator of Transcription 1 and Decreases Inducible Nitric-Oxide Synthase Expression and Nitric Oxide Production in Response to Inflammatory Stimuli J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 858 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Mogensen, R. S. Berg, S. R. Paludan, and L. Ostergaard Mechanisms of Dexamethasone-Mediated Inhibition of Toll-Like Receptor Signaling Induced by Neisseria meningitidis and Streptococcus pneumoniae Infect. Immun., January 1, 2008; 76(1): 189 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Miech Pathopharmacology of Excessive Hemorrhage in Mifepristone Abortions Ann. Pharmacother., December 1, 2007; 41(12): 2002 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Newton and N. S. Holden Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor? Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. A. Huynh, T. Hampartzoumian, J. P. Arm, J. Hunt, L. Borges, M. Ahern, M. Smith, C. L. Geczy, H. P. McNeil, and N. Tedla Down-regulation of leucocyte immunoglobulin-like receptor expression in the synovium of rheumatoid arthritis patients after treatment with disease-modifying anti-rheumatic drugs Rheumatology, May 1, 2007; 46(5): 742 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wada, R. Lu, D. Zhou, J. Chu, T. Przewloka, S. Zhang, L. Li, Y. Wu, J. Qin, V. Balasubramanyam, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor Blood, February 1, 2007; 109(3): 1156 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Chivers, W. Gong, E. M. King, J. Seybold, J. C. Mak, L. E. Donnelly, N. S. Holden, and R. Newton Analysis of the Dissociated Steroid RU24858 Does Not Exclude a Role for Inducible Genes in the Anti-Inflammatory Actions of Glucocorticoids Mol. Pharmacol., December 1, 2006; 70(6): 2084 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ayaori, S. Sawada, A. Yonemura, N. Iwamoto, M. Ogura, N. Tanaka, K. Nakaya, M. Kusuhara, H. Nakamura, and F. Ohsuzu Glucocorticoid Receptor Regulates ATP-Binding Cassette Transporter-A1 Expression and Apolipoprotein-Mediated Cholesterol Efflux From Macrophages Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 163 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stellato Post-transcriptional and Nongenomic Effects of Glucocorticoids Proceedings of the ATS, November 1, 2004; 1(3): 255 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rapizzi, S. Fossati, F. Moroni, and A. Chiarugi Inhibition of Poly(ADP-Ribose) Glycohydrolase by Gallotannin Selectively Up-Regulates Expression of Proinflammatory Genes Mol. Pharmacol., October 1, 2004; 66(4): 890 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Reddy, G. Bhattacharjee, G. Schabbauer, A. Hollis, K. Kempf, M. Tencati, M. O'Connell, M. Guha, and N. Mackman Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability J. Leukoc. Biol., July 1, 2004; 76(1): 145 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Williams, R Y Bhat, P Cheeseman, G F Rafferty, S Hannam, and A Greenough Exhaled nitric oxide in chronically ventilated preterm infants Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2004; 89(1): F88 - F89. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lahti, U. Jalonen, H. Kankaanranta, and E. Moilanen c-Jun NH2-Terminal Kinase Inhibitor Anthra(1,9-cd)pyrazol-6(2H)-one Reduces Inducible Nitric-Oxide Synthase Expression by Destabilizing mRNA in Activated Macrophages Mol. Pharmacol., August 1, 2003; 64(2): 308 - 315. [Abstract] [Full Text] [PDF] |
||||